Companies › Agenus
2 active drug programs in 53 registered trials: 39 Phase 2, 12 Phase 1, 2 Phase 3; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Balstilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Advanced Melanoma; Metastatic Colorectal Cancer; Advanced Cancer; Gastric Cancer … | Sep 2027 |
| Botensilimab Anti-CTLA-4 monoclonal antibody | CTLA4 | Phase 2 | Advanced Melanoma; Metastatic Colorectal Cancer; Gastric Cancer; Colorectal Cancer Metastatic … | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05638698 | Balstilimab | Phase 2 | Pancreas Cancer | Oncology | Dec 2024 |
| NCT05529316 | Botensilimab | Phase 2 | Advanced Melanoma | Oncology | Apr 2026 |
| NCT05529316 | Balstilimab | Phase 2 | Advanced Melanoma | Oncology | Apr 2026 |
| NCT05318469 | Balstilimab | Phase 1 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Oct 2026 |
| NCT05672316 | Botensilimab | Phase 1 | Advanced Colorectal Adenocarcinoma | Oncology | Dec 2026 |
| NCT05672316 | Balstilimab | Phase 1 | Advanced Colorectal Adenocarcinoma | Oncology | Dec 2026 |
| NCT06300463 | Botensilimab | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT06300463 | Balstilimab | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT06336902 | Botensilimab | Phase 1 | Metastatic Colorectal Adenocarcinoma | Oncology | Jan 2027 |
| NCT06336902 | Balstilimab | Phase 1 | Metastatic Colorectal Adenocarcinoma | Oncology | Jan 2027 |
| NCT05632328 | Botensilimab | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2027 |
| NCT04028063 | Botensilimab | Phase 2 | Metastatic Soft Tissue Sarcoma | Oncology | Apr 2027 |
| NCT04028063 | Balstilimab | Phase 2 | Metastatic Soft Tissue Sarcoma | Oncology | Apr 2027 |
| NCT05845450 | Botensilimab | Phase 2 | Colorectal Cancer | Oncology | May 2027 |
| NCT07735624 | Botensilimab | Phase 2 | Early Rectal Cancer | Oncology | Jun 2027 |
| NCT07735624 | Balstilimab | Phase 2 | Early Rectal Cancer | Oncology | Jun 2027 |
| NCT05627635 | Botensilimab | Phase 1 | Metastatic Colon Adenocarcinoma | Oncology | Jun 2027 |
| NCT05627635 | Balstilimab | Phase 1 | Metastatic Colon Adenocarcinoma | Oncology | Jun 2027 |
| NCT06251973 | Botensilimab | Phase 2 | Metastatic Esophageal Carcinoma | Oncology | Aug 2027 |
| NCT06251973 | Balstilimab | Phase 2 | Metastatic Esophageal Carcinoma | Oncology | Aug 2027 |
| NCT05608044 | Botensilimab | Phase 2 | Metastatic Colorectal Cancer | Oncology | Sep 2027 |
| NCT05608044 | Balstilimab | Phase 2 | Metastatic Colorectal Cancer | Oncology | Sep 2027 |
| NCT04943848 | Balstilimab | Phase 1 | Diffuse Intrinsic Pontine Glioma | Oncology | Sep 2027 |
| NCT06780787 | Botensilimab | Phase 2 | Rectal Adenocarcinoma | Oncology | Nov 2027 |
| NCT06780787 | Balstilimab | Phase 2 | Rectal Adenocarcinoma | Oncology | Nov 2027 |
| NCT03860272 | Balstilimab | Phase 1 | Advanced Cancer | Oncology | Dec 2027 |
| NCT06843434 | Botensilimab | Phase 2 | Microsatellite Stable Rectal Carcinoma | Oncology | Feb 2028 |
| NCT06843434 | Balstilimab | Phase 2 | Microsatellite Stable Rectal Carcinoma | Oncology | Feb 2028 |
| NCT06346197 | Botensilimab | Phase 3 | Gastric Cancer | Oncology | May 2028 |
| NCT06346197 | Balstilimab | Phase 3 | Gastric Cancer | Oncology | May 2028 |
| NCT06268015 | Botensilimab | Phase 2 | Colorectal Cancer | Oncology | Jul 2028 |
| NCT06268015 | Balstilimab | Phase 2 | Colorectal Cancer | Oncology | Jul 2028 |
| NCT07550088 | Botensilimab | Phase 2 | Colorectal Cancer Metastatic | Oncology | Sep 2028 |
| NCT07550088 | Balstilimab | Phase 2 | Colorectal Cancer Metastatic | Oncology | Sep 2028 |
| NCT06782932 | Balstilimab | Phase 1 | Pancreatic Cancer | Oncology | Dec 2028 |
| NCT07595874 | Botensilimab | Phase 2 | Advanced Colon Adenocarcinoma | Oncology | Dec 2028 |
| NCT07595874 | Balstilimab | Phase 2 | Advanced Colon Adenocarcinoma | Oncology | Dec 2028 |
| NCT07516366 | Botensilimab | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Dec 2028 |
| NCT07516366 | Balstilimab | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Dec 2028 |
| NCT06279130 | Botensilimab | Phase 2 | Resectable MMR-deficient Solid Tumors | Oncology | Jan 2029 |
| NCT06279130 | Balstilimab | Phase 2 | Resectable MMR-deficient Solid Tumors | Oncology | Jan 2029 |
| NCT07551596 | Botensilimab | Phase 2 | Colorectal Adenocarcinoma | Oncology | Aug 2029 |
| NCT07551596 | Balstilimab | Phase 2 | Colorectal Adenocarcinoma | Oncology | Aug 2029 |
| NCT05891821 | Balstilimab | Phase 2 | Lymphoma | Oncology | Sep 2029 |
| NCT06411691 | Botensilimab | Phase 1 | Colorectal Cancer | Oncology | Nov 2029 |
| NCT06411691 | Balstilimab | Phase 1 | Colorectal Cancer | Oncology | Nov 2029 |
| NCT06322108 | Balstilimab | Phase 2 | Non-small Cell Lung Cancer | Oncology | Apr 2030 |
| NCT06843551 | Botensilimab | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Aug 2030 |
| NCT06843551 | Balstilimab | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Aug 2030 |
| NCT07227636 | Botensilimab | Phase 2 | Colorectal Cancer | Oncology | Nov 2030 |
| NCT07227636 | Balstilimab | Phase 2 | Colorectal Cancer | Oncology | Nov 2030 |
| NCT05864534 | Botensilimab | Phase 2 | Newly Diagnosed Glioblastoma | Oncology | Jul 2031 |
| NCT05864534 | Balstilimab | Phase 2 | Newly Diagnosed Glioblastoma | Oncology | Jul 2031 |
Cash and short-term investments of $87m on 2026-09-30; operating cash outflow about $117m a year; runway about 9 months at that burn, to Jun 2027; 5 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
CrystalGenomics Taizhou Hanzhong biomedical Coherus Oncology Summit Therapeutics Innate Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.